Live
- Chandrababu holds meeting with ministers, discusses on SC Classification
- National anti-terror policy, strategy to be unveiled soon: HM Shah
- Donald Trump Effect: Gold Prices Drop Sharply in a Single Day
- Australian govt to ban social media access for children younger than 16
- ED conducts raids on multiple sellers linked to e-com players including Amazon, Flipkart
- India A vs Australia A: Contrasting outings for KL Rahul and Dhruv Jurel at Melbourne
- Lakshya and Ananya Panday Pair Up in Dharma Productions' Next Big Film
- After political furore, BJP leader withdraws slur on Sharad Pawar
- Kerala Cong cries foul over police raid on hotel rooms of women leaders, moves ECI
- Sara Ali Khan and Sidharth Malhotra Team Up for New Film by ‘Panchayat’ Director
Dr Reddy's inks pact with Gilead Sciences
Dr Reddy's Laboratories Ltd on Saturday announced it has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. that will grant the city-based drug maker right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India
Dr Reddy's Laboratories Ltd on Saturday announced it has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. that will grant the city-based drug maker right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.
Dr Reddy's will receive technology transfer from Gilead for manufacturing of this drug and needs to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries, a press release from DRL said.
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat hospitalised patients with severe Covid-19 illness. India currently does not manufacture Remdesivir.
The four companies - Hetero, Jubilant Life Sciences, Cipla and Mylan NV - with which Gilead Sciences Inc have earlier entered into non-exclusive licensing agreements are still awaiting permission from the Drug Controller General of India (DCGI) for manufacturing and distribution Remdesivir in the country.
